Australian biotech market today 13.03.09
13 March, 2009 by Kate McDonaldAlchemia, pSivida, CSL, Acrux, Cellestis
NuSep erects NxGen prospectus
12 March, 2009 by Kate McDonaldNuSep plans to raise cash for NxGen acquisition
Italy and Japan for Fermiscan
12 March, 2009 by Kate McDonaldHitachi Chemical takes option on Fermiscan licence, Italy look promising
Progen-Avexa deal goes bung
10 March, 2009 by Kate McDonaldProgen forced to drop Avexa merger after overwhelming no vote
Update: Big Pharma mega-merger dramarama
10 March, 2009 by Kate McDonaldMerck and Schering-Plough; Pfizer and Wyeth; Roche and Genentech
Polartechnics moves into Pakistan
09 March, 2009 by Kate McDonaldPakistan government orders cervical cancer screen
Arana completes Phase II
09 March, 2009 by Kate McDonaldAntibody company Arana completes Phase II trial of anti-TNF drug for psoriasis
Ring around a rosella
06 March, 2009 by Graeme O'NeillThe crimson rosella is not the only colour in town – P. elegans also comes in orange and yellow shades.
Drag lizards, queens of the desert
05 March, 2009 by Kate McDonaldShe-male lizards deceive competitors by sight but not smell
Implicit licence from Lilly
04 March, 2009 by Kate McDonaldBrisbane biopharma Implicit buys antibody program from Eli Lilly
Cephalon offers $318 million for Arana
27 February, 2009 by Kate McDonaldUS company Cephalon named as the bidder for Arana
Time to get out now: PwC
27 February, 2009 by Kate McDonaldBiotech: shut up shop now if writing’s on the wall
Takeover bid for Arana
27 February, 2009 by Kate McDonaldCash-rich Arana Therapeutics in discussion about takeover
Extra heart recruits for Mesoblast
27 February, 2009 by Kate McDonaldGood preliminary data allows further patient recruitment for heart stem cells
Tolerance for Novogen
27 February, 2009 by Kate McDonaldMarshall Edwards prostate cancer product reveals good early results
